FDA Adcomm Returns Mixed Vote on GSK's CKD Drug - Updated
An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results.
Source: biospace.com
Stay updated with breaking news from Janssen Procrit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results.
/PRNewswire/ -- Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products),...
/PRNewswire/ -- Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products),...